Press Releases
Immutep and Lonza sign agreement for cell line selection, cell banking and process development of ImmuFact(R) IMP321
Immutep and Lonza announced today an agreement for cell line selection, master cell banking and process development of ImmuFact(R) IMP321. Lonza will initiate the process development for Immutep’s lead product, using Immutep's newly-developed proprietary cell lines. Immutep announced...
Press Releases
Novasep opens new 2,000 m2 expanded Shanghai facilities to meet increasing East Asia demand
Novasep, a leading supplier of manufacturing solutions to the life sciences industries, today announces the opening of a new 2,000 m2 facility in Shanghai Pudong district, China. The site will boost Novasep's process development and engineering capabilities to...
Press Releases
N3D Unveils the Next Generation of 3D Cell Culturing System
Only days after Rainbow BioSciences closed a deal to acquire an equity interest in Nano3D Biosciences, n3D announced the release of its groundbreaking new 24-well Bio-Assembler. The new device is the latest iteration of n3D’s Bio-Assembler...
Press Releases
Rhenovia launches drug discovery programs in rare, orphan and neglected neurodegenerative diseases
Rhenovia Pharma, a leading biotech company in biosimulation applied to the discovery of new medications to treat neurodegenerative, neurological and psychiatric diseases, announces today that it has initiated drug research programs in rare, orphan and neglected diseases. ...
Press Releases
AstraZeneca files lawsuit against the FDA for decision regarding quetiapine product labelling and exclusivity
AstraZeneca today filed a lawsuit against the US Food and Drug Administration (FDA) in the US District Court for the District of Columbia to overturn the FDA’s denial on 7 March 2012 of Citizen Petitions filed by AstraZeneca...
Press Releases
Boehringer Ingelheim expands capabilities in biopharmaceutical process science
Ingelheim, Germany – Boehringer Ingelheim has expanded its biopharmaceutical development and manufacturing capabilities at its cell culture and microbial sites in Biberach, Germany and in Vienna, Austria. These expansions will enhance state-of-the art cell line...
Press Releases
Cytheris announces results of phase II study indicating that recombinant Interleukin-7 (CYT107) expands CD4 T-cells in gut mucosa of chronically HIV infected immunological non-responder...
Cytheris SA, a clinical stage biopharmaceutical company focused on development of new therapies for immune modulation, announces today results of a multi-center phase II study designed to investigate the potential of recombinant human Interleukin-7 therapy to reconstitute CD4 T-cells...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read